Disease surveillance for the COVID-19 era: time for bold changes

Simple item page
dc.contributor.authorMorgan, Oliver
dc.contributor.authorAguilera, Ximena
dc.contributor.authorAmmon, Andrea
dc.contributor.authorAmuasi, John
dc.contributor.authorFall, Ibrahima
dc.contributor.authorFrieden, Tom
dc.contributor.authorHeymann, David
dc.contributor.authorIhekweazu, Chikwe
dc.contributor.authorJeong, Eun-Kyeong
dc.contributor.authorLeung, Gabriel M
dc.contributor.authorMahon, Barbara
dc.contributor.authorNkengasong, John
dc.contributor.authorQamar, Farah Naz
dc.contributor.authorSchuchat, Anne
dc.contributor.authorWieler, Lothar
dc.contributor.authorDowell, Scott
dc.date.accessioned2022-02-17T14:28:55Z
dc.date.available2022-02-17T14:28:55Z
dc.date.issued2021
dc.description.abstractThe COVID-19 pandemic has exposed weaknesses in disease surveillance in nearly all countries. Early identification of COVID-19 cases and clusters for rapid containment was hampered by inadequate diagnostic capacity, insufficient contact tracing, fragmented data systems, incomplete data insights for public health responders, and suboptimal governance of all these elements. Once SARS-CoV-2 became widespread, interventions to control community transmission were undermined by weak surveillance of cases and insufficient national capacity to integrate data for timely adjustment of public health measures. Although some countries had little or no reliable data, others did not share data consistently with their own populations and with WHO and other multilateral agencies. The emergence of SARS-CoV-2 variants has highlighted inadequate national pathogen genomic sequencing capacities in many countries and led to calls for expanded virus sequencing. However, sequencing without epidemiological and clinical surveillance data is insufficient to show whether new SARS-CoV-2 variants are more transmissible, more lethal, or more capable of evading immunity, including vaccine-induced immunity.es
dc.description.versionVersión publicadaes
dc.identifier.citationMorgan OW, Aguilera X, Ammon A, Amuasi J, Fall IS, Frieden T, Heymann D, Ihekweazu C, Jeong EK, Leung GM, Mahon B, Nkengasong J, Qamar FN, Schuchat A, Wieler LH, Dowell SF. Disease surveillance for the COVID-19 era: time for bold changes. Lancet. 2021 Jun 19;397(10292):2317-2319. doi: 10.1016/S0140-6736(21)01096-5es
dc.identifier.urihttps://doi.org/10.1016/S0140-6736(21)01096-5es
dc.identifier.urihttp://hdl.handle.net/11447/5538
dc.language.isoenes
dc.subjectCOVID-19 / diagnosises
dc.subjectCOVID-19 / epidemiologyes
dc.subjectCOVID-19 Testinges
dc.subjectHumanses
dc.subjectPandemicses
dc.subjectPopulation Surveillance / methodses
dc.subjectSARS-CoV-2es
dc.titleDisease surveillance for the COVID-19 era: time for bold changeses
dc.typeArticlees
dcterms.sourceThe Lancetes

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Disease surveillance for the COVID-19 era.pdf
Size:
69.64 KB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services